171 related articles for article (PubMed ID: 20338068)
1. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.
Gao J; Song J; Huang H; Li Z; Du Y; Cao J; Li M; Lv S; Lin H; Gong Y
J Exp Clin Cancer Res; 2010 Mar; 29(1):28. PubMed ID: 20338068
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
3. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
Yang E; Kang HJ; Koh KH; Rhee H; Kim NK; Kim H
Int J Cancer; 2007 Aug; 121(3):567-75. PubMed ID: 17397030
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma.
Rodríguez-Jiménez FJ; Caldés T; Iniesta P; Vidart JA; Garcia-Asenjo JL; Benito M
Oncol Rep; 2007 Jun; 17(6):1301-7. PubMed ID: 17487382
[TBL] [Abstract][Full Text] [Related]
5. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment.
Yoshimura T; Nagahara M; Kuo C; Turner RR; Soon-Shiong P; Hoon DS
Epigenetics; 2011 Aug; 6(8):1001-11. PubMed ID: 21725199
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.
Omura N; Li CP; Li A; Hong SM; Walter K; Jimeno A; Hidalgo M; Goggins M
Cancer Biol Ther; 2008 Jul; 7(7):1146-56. PubMed ID: 18535405
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer.
Chen ZY; Zhang JL; Yao HX; Wang PY; Zhu J; Wang W; Wang X; Wan YL; Chen SW; Chen GW; Liu YC
Sci Rep; 2014 Dec; 4():7035. PubMed ID: 25516351
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of secreted protein acidic and rich in cysteine gene and its significance in gastric cancer.
Shao S; Zhou NM; Dai DQ
World J Gastroenterol; 2019 Dec; 25(46):6713-6727. PubMed ID: 31857774
[TBL] [Abstract][Full Text] [Related]
11. Methylation of PTCH1a gene in a subset of gastric cancers.
Du P; Ye HR; Gao J; Chen W; Wang ZC; Jiang HH; Xu J; Zhang JW; Zhang JC; Cui L
World J Gastroenterol; 2009 Aug; 15(30):3799-806. PubMed ID: 19673023
[TBL] [Abstract][Full Text] [Related]
12. Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer.
Sun XF; Sun ZY; Pan B; Li L; Shen W
Mol Biol Rep; 2012 May; 39(5):5631-6. PubMed ID: 22189542
[TBL] [Abstract][Full Text] [Related]
13. Matricellular protein SPARC/osteonectin expression is regulated by DNA methylation in its core promoter region.
Torres-Núñez E; Cal L; Suárez-Bregua P; Gómez-Marin C; Moran P; Gómez-Skarmeta JL; Rotllant J
Dev Dyn; 2015 May; 244(5):693-702. PubMed ID: 25728805
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
16. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing.
Hamada T; Goto M; Tsutsumida H; Nomoto M; Higashi M; Sugai T; Nakamura S; Yonezawa S
Cancer Lett; 2005 Sep; 227(2):175-84. PubMed ID: 16112420
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
18. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study analyzing the methylated genes in the plasma of patients with pancreatic cancer.
Park JW; Baek IH; Kim YT
Scand J Surg; 2012; 101(1):38-44. PubMed ID: 22414467
[TBL] [Abstract][Full Text] [Related]
20. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
